Skip to main content
. Author manuscript; available in PMC: 2023 Jan 5.
Published in final edited form as: Clin Cancer Res. 2022 Jun 2;28(16):3618–3629. doi: 10.1158/1078-0432.CCR-21-3189

Figure 1. Patient scheme.

Figure 1

Swimmerplot indicating timing of endocrine therapy treatment and tumor tissue sampling for each patient stratified by patient response to endocrine therapy. For each tumor sample, response to treatment defined by assessment of tumor volume change and number of biological replicates were indicated. Clinically HER2+ patients with positive immunohistochemistry (IHC) staining were highlighted in pink box.